NEXI-003

N/A

Report date: 2026/02/26 20:00:22

Base Information

Drug NameNEXI-003
Drug Alias NameNEXI003
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsProtein E6 modulators +[5] 
TargetsProtein E6Protein E7Baculoviral IAP repeat-containing protein 5
Therapy Area/IndicationsOropharyngeal Squamous Cell Carcinoma (OPSCC)Solid tumoursOropharyngeal Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNeximmune Inc
China Registration ClassN/A

Develop Information

Active CompaniesNeximmune Inc
Inactive CompaniesN/A
Active IndicationsOropharyngeal Squamous Cell Carcinoma (OPSCC)Solid tumoursOropharyngeal Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A